Hypoparathyroidism Market

Market Overview:

The 7 major hypoparathyroidism markets are expected to exhibit a CAGR of 7.72% during 2024-2034.

The hypoparathyroidism market has been comprehensively analyzed in IMARC's new report titled "Hypoparathyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypoparathyroidism refers to a rare endocrine disorder characterized by insufficient production or secretion of parathyroid hormone (PTH) by the parathyroid glands located in the neck. PTH plays an important part in regulating calcium levels in the body. When there is a deficiency of this hormone, it can lead to a range of health complications. The indications of the disease often manifest due to low blood calcium levels and can vary in severity. Common symptoms include muscle cramps, tingling sensations, muscle spasms, and weakness. Patients may also experience seizures, mood swings, and cognitive disturbances, as calcium is vital for proper nerve and muscle function. The diagnosis of hypoparathyroidism involves a combination of clinical evaluation, blood tests to measure calcium and PTH levels, and sometimes genetic testing to identify the underlying cause. Imaging studies, like ultrasound or MRI, may be used to locate the parathyroid glands and assess their condition.

The escalating utilization of thyroid or neck surgery that can cause damage to the parathyroid glands is primarily driving the hypoparathyroidism market. In addition to this, the inflating application of efficacious pharmaceutical treatments, such as synthetic PTH formulations, vitamin D analogs, and calcium supplements, is also creating a positive outlook for the market. These medications aim to normalize serum calcium levels and minimize symptoms, thereby improving the overall quality of life for individuals suffering from the disorder. Moreover, the widespread adoption of parathyroid transplantation procedure on account of its numerous benefits, like reduced dependency on pharmacological drugs, prevention of long-term complications, restoration of PTH production, etc., is further bolstering the market growth. Apart from this, the rising usage of comprehensive patient education programs, which empower individuals to better manage their condition, is acting as another significant growth-inducing factor. Additionally, the increasing collaborations among pharmaceutical companies, healthcare institutions, and research organizations to produce novel regimens that are highly effective and cost-efficient are also augmenting the market growth. Furthermore, the emerging popularity of stem cell therapy, since it help to regenerate damaged or missing parathyroid tissue responsible for producing PTH, thus regulating calcium levels in the body, is expected to drive the hypoparathyroidism market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hypoparathyroidism market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hypoparathyroidism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypoparathyroidism market in any manner.

Recent Developments:

• In January 2024, Ascendis Pharma A/S announced that YORVIPATH (palopegteriparatide, formerly TransCon PTH), a parathyroid hormone (PTH) replacement medicine recommended for the treatment of individuals with persistent hypoparathyroidism, is now accessible in Germany and Austria. YORVIPATH is the second commercially available product created using Ascendis Pharma's TransCon technology platform.
• In December 2023, Ascendis Pharma A/S stated that the US Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the therapy of adult hypoparathyroidism. In the USA, TransCon PTH (palopegteriparatide) is an experimental prodrug of parathyroid hormone (PTH [1-34]) for adult patients with hypoparathyroidism.
• In May 2023, Amolyt Pharma declared that it would begin a Phase 3 clinical trial of eneboparatide, a long-acting parathyroid hormone 1 (PTH1) receptor agonist, in individuals suffering from hypoparathyroidism after receiving End-of-Phase 2 guidelines from the US Food and Drug Administration.
• In May 2023, Extend Biosciences reported positive findings from its first-in-human trial with EXT608 for the treatment of hypoparathyroidism. An interim data analysis revealed that EXT608 was safe and well tolerated, with no significant adverse events reported. It also exhibits a dose-dependent increase in serum calcium without a concurrent increase in urine calcium.

Key Highlights:

• Anterior neck surgery is the most frequent cause of acquired hypoparathyroidism and accounts for over 75% of cases.
• The prevalence of hypoparathyroidism in the United States is estimated to be around 37 per 100,000 person-years.
• The overall prevalence of hypoparathyroidism in the EU is estimated to be 3.2 per 10,000 people in 2020, with a growth rate of about 0.04 cases per year.
• The majority of people with hypoparathyroidism are 45 years or older.
• The women-to-men ratio is roughly 3:1.

Drugs:

Rocaltrol (calcitriol) is a synthetic vitamin D analog that regulates calcium absorption from the GI tract and is used in the body. Rocaltrol is available in the form of pills carrying 0.25 mcg or 0.5 mcg calcitriol, as well as an oral solution containing one mcg/mL.

Natpara (parathyroid hormone), a subcutaneous injection used to treat hypoparathyroidism, was discovered and developed by NPS Pharmaceuticals, which Shire later bought in February 2015. Natpara is only indicated for those who cannot be adequately controlled with calcium and active forms of vitamin D alone.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hypoparathyroidism market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hypoparathyroidism market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hypoparathyroidism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hypoparathyroidism market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hypoparathyroidism market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hypoparathyroidism market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of hypoparathyroidism across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hypoparathyroidism by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hypoparathyroidism by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with hypoparathyroidism across the seven major markets?
• What is the size of the hypoparathyroidism patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hypoparathyroidism?
• What will be the growth rate of patients across the seven major markets?
   

Hypoparathyroidism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hypoparathyroidism drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypoparathyroidism market?
• What are the key regulatory events related to the hypoparathyroidism market?
• What is the structure of clinical trial landscape by status related to the hypoparathyroidism market?
• What is the structure of clinical trial landscape by phase related to the hypoparathyroidism market?
• What is the structure of clinical trial landscape by route of administration related to the hypoparathyroidism market?